COMMUNIQUÉS West-GlobeNewswire

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09/03/2026
WATERTOWN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced [...]
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
09/03/2026
Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026 Cash and Securities of $219.8 Million as of Year-End Supports Ongoing Clinical Execution [...]
Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
09/03/2026
WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' [...]
Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update
09/03/2026
- Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and the first brain [...]
Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
09/03/2026
Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 Advancing SEP-479 (PTH1R Agonist) Toward [...]
Zevra Reports Fourth Quarter and Full Year 2025 Financial Results
09/03/2026
Q4 net revenue of $34.1 million, representing 31% growth quarter-over-quarter FY 2025 net revenue of $106.5 million , driven by growth in MIPLYFFA ® net revenue to $87.4 million 2025 EPS of $1.40 basic and $1.35 diluted [...]
Lifecore Biomedical to Report Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, on March 16, 2026
09/03/2026
Webcast Scheduled for Monday, March 16 at 8:30 a.m. Eastern CHASKA, Minn., March 09, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated injectables contract development [...]
Bionano to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call Webcast on March 23, 2026
09/03/2026
SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Monday, March 23, 2026, at 4:30 p.m. Eastern Time to report [...]
AEON Biopharma Appoints John Bencich as Chief Financial Officer
09/03/2026
Veteran biotechnology leader with extensive capital markets experience joins AEON as Company advances lead asset through key regulatory milestones IRVINE, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc [...]
CapsoVision to Participate in the 38th Annual ROTH Conference
09/03/2026
- Company to participate in a fireside chat and 1x1 investor meetings on March 23, 2026 - SARATOGA, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology [...]
LifeMD Reports Fourth Quarter and Full Year 2025 Results
09/03/2026
Full year 2025 revenue grew 25% to $194.1 million; adjusted EBITDA rose 309% to $15.3 million. Fourth quarter revenue increased 4% to $46.9 million; adjusted EBITDA rose 348% to $4.8 million. Successfully launched oral [...]
Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C
09/03/2026
Post hoc analysis supports a reduction of time to first bowel movement and a consistent improvement in abdominal symptoms, including pain, discomfort, and bloating, during 12 weeks of treatment WALTHAM, Mass., March 09 [...]
Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
09/03/2026
CRANFORD, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“ Enzon ” or the “ Company ”) today announced that it has extended the expiration date for the exchange offer by the Company [...]
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
09/03/2026
– LOQTORZI ® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 million in year [...]
The Right to Religious Exemption to Vaccination Upheld in Court, according to the Journal of American Physicians and Surgeons
09/03/2026
TUCSON, Ariz., March 09, 2026 (GLOBE NEWSWIRE) -- Despite concerns about COVID vaccines, vaccine mandates are increasing in hospitals, schools, military service, and even ordinary employment, writes Andrew Schlafly in [...]
Tonix Pharmaceuticals Presented Data on TONMYA™ in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting
09/03/2026
TONMYA (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, was commercially launched in November 2025 Treatment with TONMYA provided statistically significant pain reduction in two [...]
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
09/03/2026
– The FDA assigned a PDUFA target action date of December 22, 2026 – – The NDA is based on positive data from a successful clinical program demonstrating favorable safety and blood pressure reduction in adults with [...]
Mesa Laboratories Announces CEO Transition and Appointment of Siddhartha Kadia as President and CEO
09/03/2026
LAKEWOOD, Colo., March 09, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of life science tools and critical quality control [...]
Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference
09/03/2026
CORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and [...]

Pages